RPLP2 and neoplasm: Previous study indicated that recombinant RPLP2 with Toll-like receptor 4 (TLR4) could induce the maturation and activation of DCs, and pulse tumor-specific antigen, to induce the activation of tumor-specific CD8IFN-γ T cells followed by tumor clearance [15].